Disclosures for "Rational Design of a Vaccine for Synucleinopathies Using Computationally-Derived Conformational B Cell Epitopes To Selectively Target Pathogenic Alpha-Synuclein Species"
-
Dr. Kaplan has received personal compensation for serving as an employee of ProMIS Neurosciences. Dr. Kaplan has stock in ProMIS Neurosciences. Dr. Kaplan has received intellectual property interests from a discovery or technology relating to health care.
-
The institution of Dr. Napper has received research support from NSERC. The institution of Dr. Napper has received research support from Westin Foundation.
-
Dr. Gibbs has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Promis Neurosciences.
-
Ms. Scruten has nothing to disclose.
-
Ms. Coutts has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ProMIS Neurosciences, Inc..
-
The institution of Dr. Watts has received research support from Canadian Institutes of Health Research. The institution of Dr. Watts has received research support from Weston Family Foundation.
-
Dr. Prado has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Neurochemistry. The institution of Dr. Prado has received research support from CIHR. The institution of Dr. Prado has received research support from Alzheimer's Association. The institution of Dr. Prado has received research support from Weston Family Foundation. The institution of Dr. Prado has received research support from NFRF. The institution of Dr. Prado has received research support from NSERC.
-
Dr. Cashman has received personal compensation for serving as an employee of ProMIS Neurosciences. Dr. Cashman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for IONIS. Dr. Cashman has stock in ProMIS Neurosciences. The institution of Dr. Cashman has received research support from ProMIS Neurosciences. Dr. Cashman has received intellectual property interests from a discovery or technology relating to health care.